摘要
目的 :观察血脂康对肾病综合征高脂血症的治疗作用。方法 :90例患者随机分为治疗组 6 0例 ,对照组 30例 ,两组患者均依据原发病给于相应的肾病常规治疗。同时 ,治疗组给予血脂康 ,对照组给予普拉固口服 ,于治疗前后监测患者Tch、TG、HDL C。结果 :血脂康、普拉固对于肾病综合征高脂血症均有一定的治疗作用 ,二者在降Tch方面作用相仿 (P>0 .0 5 ) ,而在降低TG升高HDL C方面血脂康优于普拉固 (均P <0 .0 5 )。结论
Objective:To investigate the clinical effect of Xuezhikang on hyperlipemia induced by nephrotic syndrome.Methods: 90 patients were divided into two groups at random:the treatment group with 60 cases and the control group with 30 cases.Both groups were treated by the routine procedure according to nephrosis. At the same time,the treatment group was given drug Xuezhikang and the control group was given drug Pulagu orally.Tch、TG and HDL C of patients before and after treatment were determined. Results: Both drugs showed a certain clinical effect on hyperlipemia induced by nephrotic syndrome and had the similar action in decreasing Tch level ( P >0.05). But Xuezhikang was superior to Pulagu in decreasing TG level and raising HDL C level ( P <0.05). Conclusions: Xuezhikang is effective for hyperlipemia induced by nephrotic syndrome.
出处
《中成药》
CAS
CSCD
北大核心
2001年第8期580-581,共2页
Chinese Traditional Patent Medicine
